Adaptimmune Therapeutics plc is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ADAP’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Adaptimmune could be a solid choice for investors.

Current Quarter Estimates for ADAP

In the past 30 days, one estimate has gone higher for Adaptimmune while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates moving from a loss of 28 cents a share 30 days ago, to earnings of 5 cents today, a significant increase. 

Current Year Estimates for ADAP

Meanwhile, Adaptimmune’s current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.05 per share 30 days ago to a loss of 72 cents per share today, a significant increase.

Bottom Line

The stock has also started to move higher lately, adding 16.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.